| Home > Publications Database > An engineered monomer binding-protein for α-synuclein efficiently inhibits the proliferation of amyloid fibrils. |
| Journal Article | DZNE-2020-07261 |
; ; ; ; ; ; ; ; ; ; ; ; ;
2019
eLife Sciences Publications
Cambridge
This record in other databases:
Please use a persistent id in citations: doi:10.7554/eLife.46112
Abstract: Removing or preventing the formation of [Formula: see text]-synuclein aggregates is a plausible strategy against Parkinson's disease. To this end, we have engineered the [Formula: see text]-wrapin AS69 to bind monomeric [Formula: see text]-synuclein with high affinity. In cultured cells, AS69 reduced the self-interaction of [Formula: see text]-synuclein and formation of visible [Formula: see text]-synuclein aggregates. In flies, AS69 reduced [Formula: see text]-synuclein aggregates and the locomotor deficit resulting from [Formula: see text]-synuclein expression in neuronal cells. In biophysical experiments in vitro, AS69 highly sub-stoichiometrically inhibited both primary and autocatalytic secondary nucleation processes, even in the presence of a large excess of monomer. We present evidence that the AS69-[Formula: see text]-synuclein complex, rather than the free AS69, is the inhibitory species responsible for sub-stoichiometric inhibition of secondary nucleation. These results represent a new paradigm that high affinity monomer binders can lead to strongly sub-stoichiometric inhibition of nucleation processes.
Keyword(s): Amyloid: antagonists & inhibitors (MeSH) ; HEK293 Cells (MeSH) ; Humans (MeSH) ; Protein Aggregation, Pathological (MeSH) ; Protein Multimerization: drug effects (MeSH) ; Recombinant Proteins: genetics (MeSH) ; Recombinant Proteins: metabolism (MeSH) ; alpha-Synuclein: metabolism (MeSH)
|
The record appears in these collections: |